ĐẶC ĐIỂM BỆNH GAN NHIỄM MỠ KHÔNG DO RƯỢU Ở BỆNH NHÂN RỐI LOẠN LIPID MÁU TẠI BỆNH VIỆN QUÂN Y 175

Dũng Nguyễn Thế; Tiến Đào Đức; Hiếu Trần Hà; Dũng Hoàng Anh

Keywords:

Dyslipidemia, Nonalcoholic fatty liver disease, FibroScan, liver steatosis, liver stiffness

Abstract

Objectives: Determining the rate and characteristics of nonalcoholic fatty liver disease (NAFLD) with dyslipidemia patients at Military Hospital 175; evaluating the degree of liver steatosis and liver stiffness measurement in NAFLD patients with FibroScan.

Subjects and methods: Cross-sectional descriptive study on 201 patients with dyslipidemia being evaluated and managed at Military Hospital 175 from January 2019 to July 2020.

Results: The rate of dyslipidemia patients with NAFLD determined by FibroScan with M probe was 80,6%. Dyslipidemia patients with NAFLD having mild – moderate - sereve steatosis on FibroScan were 35,8%; 30,9% and 33%; respectively. F0-F1, F2, F3 and F4 fibrosis stages according to Metavir evaluating by FibroScan were 93,2%; 4,3%; 1,9% and 0,6%, respectively.

Conclusions: At Military Hospital 175, nonalcoholic fatty liver disease accounts for a high rate of patients with dyslipidemia. The majority of dyslipidemia patients with NAFLD have a mild liver fibrosis assessed by FibroScan.

References

Assy N., Kaita K., Mymin D., et al. (2000). “Fatty infiltration of liver in hyperlipidemic patients”, 45 (10), pp. 1929- 1934.

Azzam H., Malnick S. J. W. j. o. h. (2015). “Non-alcoholic fatty liver disease-the heart of the matter”, 7 (10), pp. 1369.

Chalasani N., Younossi Z., Lavine J. E., et al. (2018). “The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases”, 67 (1), pp. 328-357.

Detection N. C. E. P. E. P. o., Adults T. o. H. B. C. i. (2002). "Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)". The Program.

Eslam M., Newsome P. N., Anstee Q. M., et al. (2020). “A new definition for metabolic associated fatty liver disease: an international expert consensus statement”.

Fabrellas N., Hernandez R., Graupera I., et al. (2018). “Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study”, 13 (9), pp. e0200656.

Hu Y.-Y., Dong N.-L., Qu Q., et al. (2018). “The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients”, 97 (43).

Karlas T., Petroff D., Garnov N., et al. (2014). “Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1 H-MR spectroscopy”, 9 (3), pp. e91987.

Katsiki N., Mikhailidis D. P., Mantzoros C. S. J. M. (2016). “Non-alcoholic fatty liver disease and dyslipidemia: an update”, 65 (8), pp. 1109-1123.

Vernon G., Baranova A., Younossi Z. J. A. p., et al. (2011). “Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults”, 34 (3), pp. 274-285.

Wong V. W. S., Vergniol J., Wong G. L. H., et al. (2010). “Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease”. Hepatology, 51 (2), pp. 454-462.